Celsis, Promega Team on ADME-Tox Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Celsis In Vitro Technologies, a division of life science products and lab services firm Celsis International, today announced that it is collaborating with Promega on ADME-Tox assays for hepatocytes.

Baltimore-based Celsis IVT said that it will provide pre-qualified lots of its cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including those used to study cytochrome P450 gene induction and inhibition and its GSH-Glo Glutathione assay for investigating mechanisms of hepatoxicity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.